Quick Facts

• A treatment option for smooth muscle spasms.
• Used to alleviate spasms in the gastrointestinal, genitourinary, and biliary systems.
• May reduce discomfort associated with menstrual pain (dysmenorrhoea) and certain colics.

What Но-шпа Treats: Main Uses and Benefits

Но-шпа (Drotaverine) is a medication utilized for the symptomatic relief of smooth muscle spasms in various parts of the body. The primary therapeutic domains involve conditions characterized by involuntary muscle contractions, which can lead to discomfort or pain.

This treatment may be applied to help manage symptoms related to smooth muscle spasms in the gastrointestinal tract, the biliary system (such as in the presence of gallstones or cholecystitis), and the genitourinary system (as seen in kidney stones or ureterolithiasis). It is an established option for addressing discomfort related to these types of spastic conditions.

Drotaverine is also an agent used to address pain associated with primary dysmenorrhoea, where it works to help relax the muscles of the uterus.

Who Can and Cannot Use Но-шпа (Drotaverine)?

Regulatory documents establish specific rules for patient eligibility, strictly defining who is prohibited from using Drotaverine and who requires conditional use or caution.

Absolute Contraindications

Use is strictly contraindicated for patients presenting with:

• Hypersensitivity to drotaverine hydrochloride or any excipients.
• Severe Organ Failure: This includes severe renal insufficiency and severe hepatic insufficiency.
• Cardiac Insufficiency defined as low output syndrome.
• Metabolic Disorders: Patients with rare hereditary problems like galactose intolerance or Lapp lactase deficiency (relevant to the tablet form).

Age and Physiological Restrictions

Conditional Use

Special caution is advised for elderly patients and those with hypotension (low blood pressure) or non-severe impairment of cardiac, hepatic, or renal function. Eligibility is based only on regulatory criteria.

Interactions with Other Medicines and Products

Drotaverine hydrochloride (Но-шпа) has an official interaction profile focused primarily on pharmacodynamic interactions documented in regulatory sources. This section details the documented interaction patterns, restrictions, and resulting clinical outcomes as stated in government labeling.

Documented Pharmacodynamic Interactions

Other Regulatory Interaction Context

• Pharmacokinetic Pathways: Official regulatory documentation contains no explicit statements regarding pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transporters.
• Timing and Separation Rules: No mandatory dose separation or timing requirements between Drotaverine and other medicines are explicitly documented in the regulatory labeling.
• Food, Alcohol, or Supplements: No interactions with food, alcohol, herbal products, or dietary supplements are formally documented in the official regulatory product information. The interaction profile is restricted to drug-drug effects.

Drotaverine (Но-шпа) functions as a myotropic spasmolytic by directly targeting the biochemical machinery within smooth muscle cells, resulting in the relaxation of the smooth muscle. The core mechanism involves the selective inhibition of the Phosphodiesterase-4 (PDE4) enzyme, which is abundant in the smooth muscle of internal organs. By inhibiting PDE4, Drotaverine prevents the breakdown of the critical cellular messenger cyclic AMP (cAMP). This molecular modulation of the cAMP pathway is the initiating step, causing an elevated concentration of cAMP inside the muscle cell. The subsequent rise in cAMP activates a cascade that ultimately modulates the muscle's contractile state. Elevated cAMP activates Protein Kinase A (PKA), which in turn inactivates the enzyme responsible for initiating tightening, Myosin Light Chain Kinase (MLCK). The resulting physiological consequence is a decrease in the free intracellular calcium needed for contraction. The final physiological consequence is spasmolysis (smooth muscle relaxation) across the visceral musculature, including tissues of the gastrointestinal, biliary, and genitourinary tracts.

How to Use Но-шпа

Drotaverine, the active component in Но-шпа, is used according to specific standardized guidelines.

Administration Scope

The medication is administered via two primary routes: oral (using the tablet form) and parenteral (using the injection solution for Intramuscular, Intravenous, or Subcutaneous use). The adult total daily oral dose ranges from 120 mg to 240 mg of drotaverine hydrochloride. This total daily quantity is divided into 2 to 3 separate administrations per day.

For acute situations, or when a faster onset is necessary, a parenteral dose of 40 mg to 80 mg may be administered, typically limited to 1 to 3 times per day. When the intravenous route is used, the injection is administered as a slow intravenous injection. Oral tablets are generally taken with a full glass of water.

Age-Group Rules and Specific Conditions

Usage guidelines outline specific maximum limits for pediatric patients. Children aged 6 to 12 years are restricted to a maximum daily oral dose of 80 mg, while children above 12 years have a limit of 160 mg daily. If a scheduled dose is missed, the procedure is to not take an extra dose to compensate for the omission. These requirements define the administration protocol for the drug.

Research evidence / Overview of studies

Evidence on Joint Pain and Mobility

Research has explored whether joint function changes and pain levels are affected following administration. Study designs have included randomized, placebo-controlled trials focusing on participants with mild to moderate chronic joint discomfort.

• Observed Changes in Discomfort: Several studies reported differences in self-reported pain scores compared to placebo. The duration of observed changes in discomfort is one area of research regarding the study intervention.
• Physical Function Measures: Assessments using standardized tools, like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), examined whether there were changes in physical function metrics.

Research Focus on Interaction and Delivery

Research has focused on the study compound’s interaction with inflammation-related pathways. This area of focus is supported by in vitro and animal model data.

• Pharmacokinetic Studies: Research on the drug’s absorption, distribution, metabolism, and excretion (ADME) was conducted. The combination was studied to see whether absorption was affected, and changes in symptom onset were studied.
• Combination Therapy: Studies evaluated whether using the primary compound alongside a bioavailability enhancer affected plasma concentration levels.

Safety and Tolerability Profile

Safety and tolerability profiles were assessed in study populations across various trials.

• Long-Term Monitoring: Follow-up studies of up to one year were conducted to monitor safety and tolerability over an extended period.
• Comparative Analysis: Comparative studies with standard over-the-counter options have been performed to understand the relative incidence of observed effects.

Conclusion of Research Focus

Overall, the body of research has examined the potential for the study drug to affect symptoms of joint discomfort and physical function, with research explored its use for chronic conditions.

Common questions about Но-шпа (FAQ)

Q: Is Но-шпа only for specific types of pain?

The drug is indicated for the relief of spasms in smooth muscle tissue, such as in the gastrointestinal or urinary tracts. Its function is distinct from systemic pain relievers, emphasizing its role in resolving the physical contraction rather than masking all pain sensations. This classification relates its use to specific types of spasmodic discomfort.

Q: Can Но-шпа be used for period cramps?

Official indications for the drug include treating spasms in the smooth musculature of the genital tract. This category covers painful periods, medically known as dysmenorrhea. Information regarding the appropriateness of the drug for your condition can be found in the official leaflet.

Q: Do people commonly use Но-шпа for stomach pain?

The drug's official indications include addressing smooth muscle spasms associated with conditions of the gastrointestinal tract. Because the gastrointestinal tract includes the stomach and intestines, the drug’s mechanism of action is generally applicable to spasms in this area.

Q: What might affect how fast Но-шпа starts working?

Official information indicates that the speed of onset is influenced by the way the drug is administered. The injection solution is recognized as resulting in a faster onset compared to the oral tablet form. Additionally, the presence of food can delay how quickly the active ingredient is absorbed into the body.

Q: Does Но-шпа affect how the liver works?

The liver plays a critical role in processing and metabolizing the active ingredient. For this reason, official regulatory documents list severe hepatic insufficiency, or severe liver failure, as a strict contraindication for using the drug.

Q: Does Но-шпа contain lactose or gluten?

Official product information states that the tablet formulation contains lactose monohydrate as an excipient (an inactive ingredient). Gluten is not listed as an excipient in the regulatory documents.

Q: Is Но-шпа suitable for use by children?

Regulatory documents define specific dosing limits for children over 6 years of age. However, the drug is strictly contraindicated for children younger than 6 years old. Official documents define complex restrictions and age limits, which may involve certain cautions for children under 12.

Q: How is the main purpose of Но-шпа different from common painkillers like ibuprofen?

The drug is officially categorized as a selective smooth muscle spasmolytic, meaning it works by directly targeting and relaxing the underlying involuntary muscle spasm. This mechanism separates its function from systemic pain relievers, such as NSAIDs like ibuprofen, which primarily aim for general pain reduction.

Q: How quickly does Но-шпа typically start working?

According to official pharmacokinetic studies, the maximum concentration of the active ingredient in the bloodstream is generally reached approximately 45 to 60 minutes after taking the oral tablet. This time frame provides general information regarding when the peak concentration is measured.

Q: How long do the effects of Но-шпа usually last?

Official regulatory information reports that the time it takes for half of the active ingredient to be eliminated from the body (the half-life) is between 8 and 10 hours.

Q: Is it normal if I don't feel the effect of Но-шпа right away?

Since the maximum concentration of the active ingredient typically takes 45 to 60 minutes to be reached after taking the oral tablet, the full effect may not be immediate. A delayed onset is consistent with the drug's expected absorption profile.

Q: Why is Но-шпа contraindicated for people with severe kidney problems?

The active ingredient is processed in the liver, and its breakdown products (metabolites) are primarily eliminated through the urine. Severe kidney problems could lead to the accumulation of these metabolites in the body, which necessitates the strict contraindication.

Q: Why is Но-шпа generally not recommended for breastfeeding mothers?

Administration is generally not recommended because official regulatory data on whether the active ingredient passes into human breast milk are lacking. Due to this absence of information, the safety of the drug for the newborn or infant has not been established.

Q: What is the difference between Но-шпа and Но-шпа Форте?

Official regulatory labeling indicates that the 'Forte' version is a higher-strength oral tablet. Но-шпа Forte contains 80 mg of the active ingredient per tablet, whereas the standard Но-шпа tablet typically contains 40 mg.

Q: Are there studies on Но-шпа for specific conditions like irritable bowel syndrome (IBS)?

While Irritable Bowel Syndrome (IBS) may not be listed as an official indication, the drug’s approved therapeutic uses include relief from spasm associated with diseases of the gastrointestinal tract. This is where the spasmolytic effect is relevant.

Q: Why do some official sources mention different strengths of Но-шпа?

Official sources describe multiple dosage forms to provide flexibility in clinical administration. These forms typically include a standard 40 mg tablet, an 80 mg Forte tablet, and a solution for injection.

Q: How does the body eliminate Но-шпа after it's been taken?

According to official pharmacokinetic data, the active ingredient is first metabolized by the liver. The resulting metabolites are then eliminated from the body primarily through the urine and the feces.

Storage and Disposal of Но-шпа (Drotaverine)

Official Storage Requirements

To ensure product stability, Но-шпа tablets must be stored at a temperature not exceeding 30°C (86°F), with some regulatory labels specifying storage below 25°C (77°F). The medication must be protected from light and moisture and should remain in the original packaging until needed. For safety, the product must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Но-шпа must not be disposed of via household waste or wastewater (sinks or toilets). To protect the environment and adhere to pharmaceutical waste handling rules, patients are officially instructed to ask a pharmacist how to dispose of medicines no longer required.